Anavex Life Sciences Management
Management criteria checks 2/4
Anavex Life Sciences' CEO is Chris Missling, appointed in Jul 2013, has a tenure of 12.67 years. total yearly compensation is $3.96M, comprised of 18.3% salary and 81.7% bonuses, including company stock and options. directly owns 1.63% of the company’s shares, worth $6.13M. The average tenure of the management team and the board of directors is 3 years and 11 years respectively.
Key information
Chris Missling
Chief executive officer
US$4.0m
Total compensation
| CEO salary percentage | 18.27% |
| CEO tenure | 12.7yrs |
| CEO ownership | 1.6% |
| Management average tenure | 3yrs |
| Board average tenure | 11yrs |
Recent management updates
Recent updates
Long-Term Neurology Pipeline And Precision Medicine Work Will Support A Stronger Outlook
Catalysts About Anavex Life Sciences Anavex Life Sciences is a clinical stage biopharmaceutical company focused on oral precision medicine therapies for neurological disorders such as early Alzheimer's disease, schizophrenia related conditions, Parkinson's disease, Fragile X syndrome and Rett syndrome. What are the underlying business or industry changes driving this perspective?Anavex: Negative EU Opinion Leaves Blarcamesine In Regulatory Purgatory
Feb 10We're Interested To See How Anavex Life Sciences (NASDAQ:AVXL) Uses Its Cash Hoard To Grow
May 21
Anavex: Looking At Different Statistical Approaches Before EMA Opinion
Feb 14The Misconceptions About Anavex Life Sciences' Blarcamesine Phase 2b/3 Trial In Alzheimer's Disease
Jan 10We're Interested To See How Anavex Life Sciences (NASDAQ:AVXL) Uses Its Cash Hoard To Grow
Dec 25Anavex Life Sciences: Why I Am Still Not Buying The Bull Thesis
Dec 24Anavex: EU Approval Application Is A Precipitous Moment
Dec 08Anavex, Cassava Sciences, Panax Ginseng, And The Long-Term Treatment Of Alzheimer's Disease
Nov 11Anavex: Understanding Their Latest Alzheimer's Data News With Caution
Nov 05Anavex Stock: A Risky Bet On CNS Drug Development (Rating Downgrade)
Oct 08Anavex Life Sciences: Short-Lived Spike On Latest Alzheimer's Data Not Surprising
Jul 29Companies Like Anavex Life Sciences (NASDAQ:AVXL) Are In A Position To Invest In Growth
Jul 17Here's Why We're Not Too Worried About Anavex Life Sciences' (NASDAQ:AVXL) Cash Burn Situation
Apr 01Here's Why We're Not At All Concerned With Anavex Life Sciences' (NASDAQ:AVXL) Cash Burn Situation
Sep 19We're Interested To See How Anavex Life Sciences (NASDAQ:AVXL) Uses Its Cash Hoard To Grow
May 10CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2025 | n/a | n/a | -US$40m |
| Sep 30 2025 | US$4m | US$723k | -US$46m |
| Jun 30 2025 | n/a | n/a | -US$48m |
| Mar 31 2025 | n/a | n/a | -US$47m |
| Dec 31 2024 | n/a | n/a | -US$46m |
| Sep 30 2024 | US$3m | US$700k | -US$43m |
| Jun 30 2024 | n/a | n/a | -US$42m |
| Mar 31 2024 | n/a | n/a | -US$41m |
| Dec 31 2023 | n/a | n/a | -US$43m |
| Sep 30 2023 | US$4m | US$700k | -US$48m |
| Jun 30 2023 | n/a | n/a | -US$52m |
| Mar 31 2023 | n/a | n/a | -US$53m |
| Dec 31 2022 | n/a | n/a | -US$50m |
| Sep 30 2022 | US$7m | US$586k | -US$48m |
| Jun 30 2022 | n/a | n/a | -US$45m |
| Mar 31 2022 | n/a | n/a | -US$43m |
| Dec 31 2021 | n/a | n/a | -US$41m |
| Sep 30 2021 | US$9m | US$550k | -US$38m |
| Jun 30 2021 | n/a | n/a | -US$32m |
| Mar 31 2021 | n/a | n/a | -US$28m |
| Dec 31 2020 | n/a | n/a | -US$28m |
| Sep 30 2020 | US$2m | US$550k | -US$26m |
| Jun 30 2020 | n/a | n/a | -US$26m |
| Mar 31 2020 | n/a | n/a | -US$26m |
| Dec 31 2019 | n/a | n/a | -US$26m |
| Sep 30 2019 | US$3m | US$513k | -US$26m |
Compensation vs Market: Chris's total compensation ($USD3.96M) is above average for companies of similar size in the US market ($USD2.36M).
Compensation vs Earnings: Chris's compensation has increased whilst the company is unprofitable.
CEO
Chris Missling (59 yo)
Dr. Christopher U. Missling, also known as the Chris, MS, Ph D., MBA, has been the Chief Executive Officer and President at Anavex Life Sciences Corp. since July 05, 2013 and also serves as its Director an...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 12.7yrs | US$3.96m | 1.63% $ 6.1m | |
| Principal Financial Officer & Treasurer | 10.4yrs | US$555.27k | 0.025% $ 93.2k | |
| VP of Corporate | no data | no data | no data | |
| Senior Vice President of Nonclinical Development | 4.8yrs | no data | no data | |
| Vice President & Head of Biostatistics | 3yrs | no data | no data | |
| Senior Vice President of Clinical Development | 1.8yrs | no data | no data | |
| Senior VP & Head of Research and Development | 1.8yrs | no data | no data | |
| Senior VP & Global Head of Neurology | less than a year | no data | no data |
Experienced Management: AVXL's management team is considered experienced (3 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 12.7yrs | US$3.96m | 1.63% $ 6.1m | |
| Independent Chairman | 4.8yrs | US$364.06k | 0% $ 0 | |
| Member of the Scientific Advisory Board | 11yrs | no data | no data | |
| Member of the Scientific Advisory Board | 15.1yrs | no data | no data | |
| Member of the Scientific Advisory Board | 12.3yrs | no data | no data | |
| Member of the Scientific Advisory Board | 12.3yrs | no data | no data | |
| Member of the Scientific Advisory Board | no data | no data | no data | |
| Member of the Scientific Advisory Board | 11.8yrs | no data | no data | |
| Member of the Scientific Advisory Board | 11yrs | no data | no data | |
| Member of the Scientific Advisory Board | 9.3yrs | no data | no data | |
| Independent Director | 9.1yrs | US$348.06k | 0.0054% $ 20.3k | |
| Lead Independent Director | 8yrs | US$364.06k | 0% $ 0 |
Experienced Board: AVXL's board of directors are seasoned and experienced ( 11 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/03/23 17:27 |
| End of Day Share Price | 2026/03/23 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/09/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Anavex Life Sciences Corp. is covered by 10 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Caroline Palomeque | Berenberg |
| Yun Zhong | Brean Capital Historical (Janney Montgomery) |
| Jason Kolbert | D. Boral Capital LLC. |